A phase II study of Catrix-S in solid tumors.
Catrix-S is an acidic mucopolysaccharide complex derived from bovine tracheal cartilage. This material was administered by weekly subcutaneous injection (5.0-7.5 g/week) to nine patients with progressive metastatic malignancy. One complete response was seen in a patient with metastatic renal cell carcinoma to the lungs. Eight patients had progression of their disease. No undue toxicity and no consistent immunologic alteration was noted.
D000970:Antineoplastic Agents; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000556:secondary; D004341:Drug Evaluation; D006801:Humans; D007279:Injections, Subcutaneous; D007680:Kidney Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000145:classification / Q000187:drug effects; D014020:Tissue Extracts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014020:Tissue Extracts; C006931:bovine cartilage extract